First Product Utilizing Amferia Antimicrobial Technology Launched in Europe for Animal Wound Care - Amferia AB

The Snögg BactiDefend Dressing, a new product in animal wound care using Amferia’s proprietary antimicrobial technology, has been launched for professional veterinary use across several European countries.

The introduction of BactiDefend is the result of a partnership between Amferia and Orkla Wound Care, released under Orkla’s Snögg Animal Care brand. This collaboration aims to address the growing need for effective wound care and bacterial reduction in wounds of both small and large animals, especially in the light of increasing concerns over antibiotic-resistant infections.

Amferia has conducted extensive clinical testing throughout Europe, receiving positive feedback from veterinary clinics. “Veterinarians report reduced bacterial load and enhanced wound healing with this new product,” says Anand Rajasekharan, CEO of Amferia.“I would like to emphasize that Orkla Wound Care's expertise supports Amferia’s goal of combating antibiotic-resistant infections in animals. The BactiDefend dressing represents a joint effort in combining advanced technology and commercial strategy aimed at meeting significant market needs in animal health”

Read more about BactiDefend.

Amferia technology—inspired by the immune system

Antimicrobial peptides are known for their ability to kill bacteria due to their positive electrostatic charge, which attracts the negatively charged bacteria. This allows peptides to puncture bacterial membranes and destroy the cells. However, their fragility in biological environments has been a major challenge to developing peptides as a viable treatment—naturally occurring enzymes in the human—or animal—body can destroy them within seconds.

Amferia's patented hydrogel platform addresses this challenge for the first time by encasing the peptides in a solid protective hydrogel. This design shields the vulnerable facets of peptides from natural enzymes while allowing their bacteria-killing structures to remain exposed and active. The hydrogel is then applied to wounds with topical dressings, meaning it can be used as a medical device, which reduces the need for time-consuming clinical trials.

= = =

About Amferia

Amferia's antimicrobial amphiphilic hydrogel kills bacteria, even resistant bacteria without harming the body. The material was developed through several years of research in collaboration with Swedish Chalmers University of Technology. Amferia's innovative, anti-microbial solution can be used on wide-ranging wounds, from simple skin injuries to post-operative wounds, chronic wounds, and trauma and burn wounds. The first product from this technology platform is a wound-care dressing for dry-to-low exuding wounds. Amferia has ongoing clinical investigations in Europe and is seeking CE marking and FDA clearance for human application.

Read more about the products, team, technology and publications at www.amferia.com

About Orkla Wound Care

Orkla Wound Care has a long tradition of developing, manufacturing and distributing market-leading products within wound care and first aid. Orkla Wound Care is a part of the Orkla group, a publicly listed company on the Norwegian Stock Exchange. Orkla Group is known for its active portfolio management targeting fast-growing consumer segments and markets.

About Snögg Animal Care

Snögg Animal Care has more than 40 years of experience in animal wound care. Developed in co-operation with veterinarians and animal wound care experts, their products are intended for animal use, with a focus on animal well-being. Learn more at https://snogg.com

= = =

For more information, please contact:Anand Rajasekharan, CEO, Amferia AB, [email protected], +46 762 981 238.